Omalizumab biosimilar - Glenmark Pharmaceuticals

Drug Profile

Omalizumab biosimilar - Glenmark Pharmaceuticals

Alternative Names: GBR 310

Latest Information Update: 05 May 2017

Price : $50

At a glance

  • Originator Glenmark Pharmaceuticals Ltd
  • Class Antiallergics; Antiasthmatics; Monoclonal antibodies
  • Mechanism of Action IgE receptor antagonists; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Allergic asthma; Urticaria

Most Recent Events

  • 25 Apr 2017 Clinical trials in Allergic asthma (In volunteers) in USA (Parenteral)
  • 25 Apr 2017 Clinical trials in Urticaria (In volunteers) in USA (Parenteral)
  • 25 Apr 2017 US FDA approves IND application for Omalizumab biosimilar in Allergic asthma and Urticaria (In volunteers)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top